Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...
The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate. Luspatercept (Reblozyl; Bristol Myers Squibb) can reduce ...
The study's lead author said patients would experience improved quality of life due to fewer transfusions and fewer trips to the clinic to receive treatment. More patients at risk of anemia from lower ...
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating ...
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, ...
The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell (RBC) ...
Luspatercept-aamt improved red blood cell transfusion independence with a concurrent hemoglobin increase among certain patients with myelodysplastic syndrome, according to the agent’s manufacturer.
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes. Background: Anemia is an important complication of MPN-associated ...
Reblozyl regulates late-stage red blood cell (RBC) maturation to potentially reduce or eliminate the need for regular RBC transfusions Reblozyl is the first and only erythroid maturation agent to be ...
Myelodysplastic syndromes (MDS) — clonal stem-cell disorders — are characterized by anemia and a risk for transformation to leukemia. A mainstay of treatment in low-risk or intermediate-risk patients ...
Two drugmakers have submitted an approval application to the Food and Drug Administration for a drug to treat a rare blood disorder and a type of blood cancer. Cambridge, Massachusetts-based Acceleron ...
Credit: Shutterstock. Researchers sought to determine whether luspatercept would improve outcomes in patients with nontransfusion-dependent β-thalassemia. The following article features coverage from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback